How Analysts Feel About AnaptysBio, Inc. (ANAB) After Today’s Significant Increase?

The stock of AnaptysBio, Inc. (NASDAQ:ANAB) is a huge mover today! The stock increased 3.70% or $1.58 during the last trading session, reaching $44.42. About 194,766 shares traded. AnaptysBio, Inc. (NASDAQ:ANAB) has declined 32.36% since September 13, 2018 and is downtrending. It has underperformed by 32.36% the S&P500.
The move comes after 7 months positive chart setup for the $1.20 billion company. It was reported on Sep, 13 by We have $48.42 PT which if reached, will make NASDAQ:ANAB worth $108.18 million more.

Analysts await AnaptysBio, Inc. (NASDAQ:ANAB) to report earnings on November, 14. They expect $-1.17 earnings per share, down 77.27 % or $0.51 from last year’s $-0.66 per share. After $-0.89 actual earnings per share reported by AnaptysBio, Inc. for the previous quarter, Wall Street now forecasts 31.46 % negative EPS growth.

More notable recent AnaptysBio, Inc. (NASDAQ:ANAB) news were published by: which released: “The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin’s Parkinson’s Add-On Therapy Approved – Benzinga” on August 28, 2019, also with their article: “The Daily Biotech Pulse: Ra Medical Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform – Benzinga” published on August 21, 2019, published: “AnaptysBio finance chief bids adieu – Seeking Alpha” on August 19, 2019. More interesting news about AnaptysBio, Inc. (NASDAQ:ANAB) were released by: and their article: “AnaptysBio Prepares for a Potential Gear Shift – The Motley Fool” published on August 10, 2019 as well as‘s news article titled: “Here’s Why AnaptysBio Shares Are Slipping Today – The Motley Fool” with publication date: August 20, 2019.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $1.20 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

AnaptysBio, Inc. (NASDAQ:ANAB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.